Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20869029 | 0.90 | ALDH1A1 (0.48) | LMNARAB9ASMN1; SMN2AAK1MEN1 | |
| SCHEMBL30101803 | 0.90 | ALDH1A1 (0.48) | LMNARAB9ASMN1; SMN2AAK1MEN1 | |
| SCHEMBL3413974 | 0.85 | ALDH1A1 (0.54) | LMNASMN1; SMN2KDM4EMEN1HTT | |
| SCHEMBL30101817 | 0.84 | AAK1 (0.55) | RAB9ASMN1; SMN2KDM4EAAK1MEN1 | |
| SCHEMBL4482701 | 0.84 | CA12 (0.47) | HPGDRAB9AAAK1ALDH1A1 | |
| SCHEMBL23275232 | 0.83 | KDM4E (0.51) | LMNAHPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3418906 | 0.82 | CCR5 (0.64) | LMNARAB9ASMN1; SMN2MEN1HTT | |
| SCHEMBL30101820 | 0.82 | NPY1R (0.44) | LMNAAAK1MEN1HTTKMT2A | |
| SCHEMBL4471744 | 0.82 | KDM4A (0.44) | NPC1RAB9ASMN1; SMN2AAK1 | |
| SCHEMBL30101829 | 0.82 | AAK1 (0.46) | NPC1RAB9ASMN1; SMN2AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411377-A1 | SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS | NORTHWESTERN UNIVERSITY | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411377-A1 | SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS | NOS3, NOS1, NOS2 | LMNA 2172/4885HPGD 56/4885NPC1 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.